University of Pittsburgh
Welcome,         Profile    Billing    Logout  
 1089 Trials 
838 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Donahoe, Michael
IMPALA-2, NCT04544293 / 2020-001263-85: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Active, not recruiting
3
160
Europe, Canada, Japan, US, RoW
Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo
Savara Inc., Savara ApS,
Autoimmune Pulmonary Alveolar Proteinosis
11/23
11/24
Collins, Michael T
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
VARVARA, NCT05907096: ARGX-117 in Deceased Donor Kidney Transplant Recipients At Risk for Delayed Graft Function

Recruiting
2
102
Europe, Canada, US, RoW
ARGX-117, Placebo
argenx
Delayed Graft Function
04/26
12/26
FUSE-UK, NCT05708963: The U.K. Embryologist Fatigue Study

Completed
N/A
123
US
TMRW Life Sciences, Dudley Associates Healthcare Marketing & Communications
Fatigue, Stress, Burnout, Professional, Musculoskeletal Pain, Back Pain, Neck Pain, Headache, Dizziness, Sleep Disturbance, Chest Pain, Syncope, Cardiovascular Diseases, Shortness of Breath, Gastrointestinal Diseases
01/23
02/23
ECLIPSE, NCT03108456: Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The Trial

Active, not recruiting
N/A
2005
US
Orbital Atherectomy, Balloon
Abbott Medical Devices, Cardiovascular Research Foundation, New York
Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
06/24
06/25
TARGET-IV_NA, NCT04562532: Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

Active, not recruiting
N/A
1720
Europe, Canada, US
Microport Firehawk stent, MicroPort Firehawk rapamycin target eluting stent, 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
12/23
06/27
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Recruiting
N/A
1252
Europe, Canada, US
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Abiomed Inc.
Left Ventricular Dysfunction, Coronary Artery Disease
03/26
10/27
Kirkwood, John M
ATLAS-IT-05, NCT04796194: Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma

Active, not recruiting
2
20
Europe, US
LTX-315 in combination with pembrolizumab
Lytix Biopharma AS, Laboratory Corporation of America, OWL
Advanced Melanoma
12/24
12/24
NCT03743766: Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Completed
2
42
US
Relatlimab, BMS-986016, Nivolumab, BMS-936558, Relatlimab + Nivolumab, BMS-986016 and BMS-936558
John Kirkwood, Bristol-Myers Squibb
Melanoma
07/24
07/24
NCT02535078 / 2015-002971-12: Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Checkmark OS data from trial in combination with durvalumab and tremelimumab for cutaneous melanoma
Jun 2022 - Jun 2022: OS data from trial in combination with durvalumab and tremelimumab for cutaneous melanoma
Withdrawn
1/2
113
US
Tebentafusp (IMCgp100)
Immunocore Ltd, AstraZeneca
Malignant Melanoma
06/23
09/23
NCT04370587: A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Recruiting
1/2
64
US, RoW
T3011, T3011 + pembrolizumab
ImmVira Pharma Co. Ltd
Solid Tumor, Melanoma, HNSCC, Sarcoma, Squamous Cell Carcinoma, NSCLC
10/23
10/25
NCT04157517: A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Terminated
1/2
45
US, RoW
Modakafusp Alfa, TAK-573, Pembrolizumab
Takeda
Neoplasms, Melanoma
12/23
12/23
NCT04688658: Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

Active, not recruiting
1/2
13
US
Nivolumab, Opdivo, AG013736, Duvelisib, Copiktra
John Kirkwood, Secura Bio, Inc., Bristol-Myers Squibb
Unresectable Melanoma
02/24
12/28
Ramanathan, Ramesh K
NCT01959139: S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Completed
1/2
126
US
PEGPH20, Pegylated Recombinant Human Hyaluronidase, Oxaliplatin, Eloxatin, NSC-266046, Leucovorin, leucovorin calcium, Irinotecan, CPT-11, NSC-616348, 5-fluorouracil, 5-FU, Adrucil, NSC-19893
SWOG Cancer Research Network, National Cancer Institute (NCI), Halozyme Therapeutics
Metastatic Pancreatic Adenocarcinoma
04/19
11/23
NCT05074472: A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

Completed
1/2
35
US
ZB131
ZielBio, Inc.
Solid Tumor, Adult, Pancreatic Ductal; Adenocarcinoma, Ovarian Serous Adenocarcinoma, Biliary Cancer Metastatic, Ovarian Serous Cystadenocarcinoma
08/23
09/23
NCT02925689: Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

Active, not recruiting
1
122
US, Canada
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436A, GSK2118436, Laboratory Biomarker Analysis, Pharmacogenomic Study, PHARMACOGENOMIC, Pharmacological Study
Mayo Clinic, GlaxoSmithKline, National Cancer Institute (NCI)
BRAF Gene Mutation, Hepatic Complication, Renal Failure, Solid Neoplasm
07/19
 
Newman, Anne
RIGHT, NCT05727384: Improving Physical Function in Older Adults Using an Anti-inflammation Drug: the Study

Recruiting
2
60
US
Clazakizumab, Placebo
Anne B. Newman, CSL Behring
Inflammation, Frailty
01/26
06/26
Lieberman, Frank S
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
HTX-GBM-01, NCT05736406: A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma

Recruiting
1/2
12
US
5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2, Pentalafen®, 5-aminolevulinic acid hydrochloride, Heliance® Solution, 5-ALA PDT, 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2
Hemerion Therapeutics
Primary Glioblastoma
12/25
07/26
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
Riddler, Sharon
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Completed
2
110
US
CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg
National Institute of Allergy and Infectious Diseases (NIAID), AbbVie
HIV-1-infection
06/24
06/24
NCT06071767: Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

Recruiting
1/2
45
US, RoW
ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, 3BNC117-LS, Teropavimab, GS-2872, 10-1074-LS, Zinlirvimab, Placebo
National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Gilead Sciences
HIV-1-infection
04/28
08/29
NCT05854381: To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV

Active, not recruiting
1
95
US, RoW
VIR-1388, Placebo
Vir Biotechnology, Inc., National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network
HIV I Infection
11/25
11/27
Handen, Benjamin L
NCT05418023: Validation of a Salivary miRNA Diagnostic Test for ASD

Recruiting
N/A
6604
US
Salivary Collection, Adaptive Assessment, Medical and Demographic questionnaire, Autism Assessment, Intellectual Development Assessment
Quadrant Biosciences Inc., University of California, Irvine, Holland Bloorview Kids Rehabilitation Hospital, Children's Hospital of Philadelphia, MetroHealth Medical Center, University of Rochester, Nationwide Children's Hospital, Children's Hospital Medical Center, Cincinnati, University of Pittsburgh, University of Massachusetts, Worcester, Children's Hospital Los Angeles, Prisma Health-Upstate, University of Virginia, State University of New York - Upstate Medical University, Rush University, Seattle Children's Hospital, Drexel University, Emory University
Autism Spectrum Disorder, Developmental Delay
07/23
07/23
Shneider, Benjamin
NCT02055768: Safety and Efficacy Study of the Intestinal Bile Acid Transport (IBAT) in the Reduction of Pruritus in ALGS

Not yet recruiting
2
24
US, Canada
LUM001 70 ug/kg/day, Intestinal Bile Acid Transport (IBAT) Inhibitor, Placebo, LUM001 140 ug/kg/day
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Lumena Pharmaceuticals, Inc.
Pruritus, Alagille Syndrome
02/15
05/15
Luketich, James D
NCT05591053: Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans

Recruiting
N/A
70
US
ActivSight
Activ Surgical, University of Pittsburgh Medical Center, West Penn Allegheny Health System
Esophagus Cancer, Esophageal Cancer, Esophageal Neoplasms, Esophageal Diseases, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophagus SCC, Esophagus Tumor, Esophagus Adenocarcinoma, Esophagus Neoplasm
01/25
01/25
Ramalingam, Suresh
LAURA, NCT03521154 / 2018-001061-16: A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Hourglass Jan 2022 - Dec 2023 : Acceptance of regulatory submission in US (based on LAURA trial) for unresectable NSCLC
Hourglass Jan 2022 - Dec 2023 : From LAURA trial for unresectable EGFRm stage III NSCLC
Active, not recruiting
3
216
Europe, Japan, US, RoW
Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg
AstraZeneca
Non Small Cell Lung Cancer (Stage III)
01/24
06/26
TROPION-Lung10, NCT06357533: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Recruiting
3
675
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, Rilvegostomig, AZD2936, Pembrolizumab, KEYTRUDA
AstraZeneca, Daiichi Sankyo
Non-Small Cell Lung Cancer
04/28
05/30
NCT03847519: Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Completed
1/2
24
US
ADXS-503, Lm immunotherapy, A503, Pembrolizumab, Keytruda, pembro
Advaxis, Inc.
Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma
02/22
02/22
NCT03917381 / 2018-003402-63: GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Active, not recruiting
1/2
429
Europe, US, RoW
Acasunlimab, GEN1046, DuoBody®-PD-L1x4-1BB, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Genmab, BioNTech SE
Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer
02/26
02/26
Becker, Dorothy
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Completed
1
47
US
NNC0361-0041, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S
Type I Diabetes
08/23
04/24
Caritis, Steve N
NCT04183452: 17-OHPC in Pregnancy: IM vs SC Routes

Terminated
N/A
24
US
17-Hydroxyprogesterone Caproate 250 mg IM Dose, 17-OHPC, 17-Hydroxyprogesterone Caproate 275 mg SC Dose
Steve N. Caritis, MD, AMAG Pharmaceuticals, Inc.
Preterm Birth
04/23
04/23
McCann, Sue A
NCT05157581: Extracorporeal Photopheresis in Sezary Syndrome

Recruiting
2
15
US
Extracorporeal photopheresis (ECP), ECP, photopheresis, Methoxsalen Injection, Uvadex
Oleg E. Akilov, MD, PhD, Mallinckrodt
Sezary Syndrome
12/25
12/26
Ghogawala, Zoher
TLIF, NCT04073563: Transforaminal Lumbar Interbody Fusion

Recruiting
N/A
1017
US, RoW
Infuse™ Bone Graft (Infuse™), Intervertebral body fusion device and Medtronic posterior Fixation Systems
Medtronic Spinal and Biologics
Degenerative Disease of the Lumbosacral Spine
04/26
04/28
Lewis, David A
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
RAINBOW, NCT04061512: Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

Recruiting
2/3
148
Europe
Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib
University College, London, Janssen-Cilag Ltd.
Waldenstrom Macroglobulinemia
03/30
03/30
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
07/27
ZEBRA, NCT05635162: Zanubrutinib Plus Rituximab for Patients with Indolent Mantle Cell Lymphoma

Recruiting
2
50
Europe
Zanubrutinib, Rituximab
University College, London, BeiGene
Mantle Cell Lymphoma
10/28
10/28
NCT05463263: A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Recruiting
1/2
180
Europe, US
STP938
Step Pharma, SAS
Lymphoma, B-Cell, Lymphoma, T-Cell
12/25
12/25
Haller, Michael J
INHALE-1, NCT04974528: Afrezza® Study in Pediatrics

Active, not recruiting
3
319
US
Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir®
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
10/24
05/25
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Recruiting
2
78
US
Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer
Diabetes Mellitus, Type 1
06/26
06/27
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Completed
1
47
US
NNC0361-0041, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S
Type I Diabetes
08/23
04/24
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes

Not yet recruiting
N/A
1500
US
Continuous Glucose Monitoring
Medtronic Diabetes
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
12/25
12/25
Schneider, Michael
PreCyssion, NCT05170269 / 2020-002383-32: Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14

Active, not recruiting
3
80
Europe
BT097, Cytotect CP Biotest 100 U/mL solution for infusion
Biotest, Biotest AG
Congenital Cytomegalovirus Infection
12/23
08/24
Ragni, Margaret V
NCT03734588: Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors

Completed
1/2
4
US
SPK-8016
Spark Therapeutics
Adeno-Associated Virus (AAV), Blood Coagulation Disorder, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, Factor VIII (FVIII), Factor VIII (FVIII) Deficiency, Factor VIII (FVIII) Gene, Factor VIII (FVIII) Protein, Genetic Diseases, Inborn, Genetic Diseases, X-Linked, Gene Therapy, Gene Transfer, Hematologic Diseases, Hemorrhagic Disorders, Recombinant, Vector, Inhibitors
10/20
01/23
NCT03003533: A Gene Transfer Study for Hemophilia A

Completed
1/2
25
Canada, US, RoW
SPK-8011
Spark Therapeutics, Inc.
Hemophilia A
12/23
12/23
NCT04770935: To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)

Completed
1
6
Europe, US
efanesoctocog alfa (BIVV001)
Bioverativ, a Sanofi company
Von Willebrand's Disease (VWD)
12/22
12/22
B-Natural, NCT02502409: Natural History Study of Factor IX Treatment and Complications

Active, not recruiting
N/A
550
US
Standard care with blood and urine sample collection
Skane University Hospital, Indiana Hemophilia &Thrombosis Center, Inc., Bioverativ Therapeutics Inc., Swedish Orphan Biovitrum
Factor IX Deficiency
06/19
12/21
NCT04055051: ATHN 11: Liver Transplantation Outcomes Study

Completed
N/A
86
US
American Thrombosis and Hemostasis Network, BioMarin Pharmaceutical
Hemophilia A and B, Liver Transplantation
12/22
12/22
ATHN 9, NCT03853486: Severe VWD Natural History Study

Active, not recruiting
N/A
108
US
American Thrombosis and Hemostasis Network, Takeda
Von Willebrand Diseases
12/24
01/25
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Saba, Samir
AVANT GUARD, NCT06096337: Pulsed Field Ablation (PFA) Vs Anti-Arrhythmic Drug (AAD) Therapy As a First Line Treatment for Persistent Atrial Fibrillation

Recruiting
N/A
520
Europe, Canada, US, RoW
FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
Boston Scientific Corporation
Persistent Atrial Fibrillation
12/25
12/27
AID MI, NCT05073419: Arrhythmia Detection After MI

Recruiting
N/A
200
US
Standard of Care, Control, ICM Implantation, ICM
Samir Saba, Abbott
Acute Myocardial Infarction
10/25
10/25
CATALYST, NCT04226547: Amplatzer Amulet LAAO Vs. NOAC

Recruiting
N/A
2650
Europe, Canada, Japan, US, RoW
Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Amplatzer Amulet LAA Occluder, Non-Vitamin K Oral Antagonists, NOAC
Abbott Medical Devices
Atrial Fibrillation, Stroke, Bleeding
08/27
08/30
Bahary, Nathan
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
NCT05766748: Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Recruiting
1/2
30
US
Azeliragon, TTP488
Cantex Pharmaceuticals
Metastatic Pancreatic Cancer
02/25
05/25
Akilov, Oleg
TELLOMAK, NCT03902184 / 2018-003969-33: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Checkmark Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Dec 2022 - Dec 2022: Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Checkmark Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Sep 2022 - Sep 2022: Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Checkmark Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021
More
Active, not recruiting
2
170
Europe, US
IPH4102, lacutamab
Innate Pharma
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
10/23
01/26
NCT05157581: Extracorporeal Photopheresis in Sezary Syndrome

Recruiting
2
15
US
Extracorporeal photopheresis (ECP), ECP, photopheresis, Methoxsalen Injection, Uvadex
Oleg E. Akilov, MD, PhD, Mallinckrodt
Sezary Syndrome
12/25
12/26
ST-001-010, NCT04234048: Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Recruiting
1
46
US
Fenretinide, nanoFenretinide, ST-001, 4-HPR, N-(4-hydroxyphenyl)retinamide, N-(4-hydroxyphenyl)-all-trans-retinamide
SciTech Development, LLC, Rush University Medical Center
T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified, Primary Cutaneous T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Unspecified, Cutaneous T-cell Lymphoma, Follicular T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Sézary's Disease, Mycosis Fungoides
05/25
11/25
III, Charles F Reynolds
OVATION 2, NCT03393884: Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer

Checkmark Presentation of OVATION 2 data in advanced ovarian cancer
Mar 2021 - Mar 2021: Presentation of OVATION 2 data in advanced ovarian cancer
Active, not recruiting
1/2
130
Canada, US
IMNN-001, Carboplatin, Paclitaxel
Imunon
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
07/24
11/25
Pilewski, Joseph M
BOSTON-2, NCT03656926 / 2018-003205-25: Efficacy + Safety of Liposome Cyclosporine a to Treat Bronchiolitis Obliterans Post Single Lung Transplant

Completed
3
220
Europe, US, RoW
Liposomal Cyclosporine A, L-CsA, Standard of Care, SoC
Zambon SpA, BREATH Therapeutics Inc.
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
03/24
03/24
BOSTON-1, NCT03657342 / 2018-003204-39: Efficacy + Safety of Liposome Cyclosporine a to Treat Bronchiolitis Obliterans Post Single Lung Transplant

Completed
3
220
Europe, US, RoW
Liposomal Cyclosporine A, L-CsA, standard of care, SoC
Zambon SpA, BREATH Therapeutics Inc.
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
04/24
04/24
NCT05641298: Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations

Withdrawn
2
80
US
Sodium Fusidate, ACG-701, ARV-1801, Placebo
Aceragen
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
09/23
09/23
NCT02694393: Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis

Terminated
1/2
4
US
sodium nitrite, AIR001
Schmidhofer, Mark, MD, Mast Therapeutics, Inc., Cystic Fibrosis Foundation
Cystic Fibrosis
07/22
07/22
NCT06159725: A Study to Evaluate the Safety of CMTX-101 in People with Cystic Fibrosis

Recruiting
1/2
41
US
CMTX-101, Placebo
Clarametyx Biosciences, Inc.
Persistent Infection, Cystic Fibrosis
08/25
08/25
NCT06052293: Phase 1 Study to Assess Safety and Efficacy of ANG003

Completed
1
51
US
ANG003, Dose Level 1, Dose Level 2, Dose Level 3, and Dose Level 4.
Anagram Therapeutics, Inc.
Exocrine Pancreatic Insufficiency
07/24
07/24
Kaminski, Naftali
STOP-IPF, NCT04598919: Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis

Active, not recruiting
1/2
49
US
Saracatinab, Placebo
National Jewish Health, Yale University, Icahn School of Medicine at Mount Sinai, AstraZeneca, National Center for Advancing Translational Sciences (NCATS), Baylor University, International Center for Health Outcomes and Innovation Research
Idiopathic Pulmonary Fibrosis (IPF)
09/24
06/25
Miller, Elizabeth
NCT04501939: Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

Active, not recruiting
2
5
US
Cirmtuzumab, Zilovertamab, Venetoclax, VENCLEXTA
University of California, San Diego, Oncternal Therapeutics, Inc
Chronic Lymphocytic Leukemia
07/25
07/25
NCT04294160: A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Terminated
1
122
Europe, Canada, US, RoW
Dabrafenib, DRB436, Tafinlar, LTT462, Trametinib, TMT212, Mekinist, LXH254, TNO155, Spartalizumab, PDR001, Tislelizumab, VDT482, BGBA317
Novartis Pharmaceuticals
BRAF V600 Colorectal Cancer
09/24
09/24
Bauman, Julie
NCT03153982: Ruxolitinib in Operable Head and Neck Cancer

Terminated
2
16
US
Ruxolitinib, Jakafi
University of California, San Francisco, Incyte Corporation
Head and Neck Squamous Cell Carcinoma
10/23
10/23
KEYNOTE-A78, NCT03978689: A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Active, not recruiting
1
85
US
CUE-101, KEYTRUDA®, Pembrolizumab, Pembrolizumab
Cue Biopharma, Merck Sharp & Dohme LLC
Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma
11/24
05/25
Wukich, Dane
ALIGN3D, NCT03740282: Early Weight-Bearing After the Lapiplasty Procedure

Active, not recruiting
N/A
183
US
Lapiplasty
Treace Medical Concepts, Inc.
Hallux Valgus, Bunion
05/23
05/26
Rosen, Clark
REVIVE, NCT05421689: Autologous Muscle Derived Cells for Treatment of Tongue Dysphagia

Active, not recruiting
1/2
66
US
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR), Autologous muscle derived stem cells, Placebo, identical placebo composed of the same cryopreservation medium used for AMDC-GIR
University of California, Davis, California Institute for Regenerative Medicine (CIRM), Cook MyoSite
Oropharyngeal Dysphagia
12/26
12/26
Dunn, Michael
EBONI, NCT05514509: A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

Recruiting
4
250
US
APRETUDE, Cabotegravir tablet
ViiV Healthcare
HIV Infections
09/25
09/25
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Active, not recruiting
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
02/25
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension

Enrolling by invitation
3
1400
Europe, Canada, US, RoW
lorundrostat, Placebo
Mineralys Therapeutics Inc.
Hypertension
12/25
12/26
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Active, not recruiting
2
285
US
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
01/25
02/25
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Completed
2
797
NA
ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline
AEON Biopharma, Inc., PPD
Migraine
06/24
08/24
Corcoran, Timothy E
NCT05755932: Study to Assess Effect of HFO MDI Propellant on Mucociliary Clearance Vs. HFA MDI Propellant in Healthy Participants

Completed
3
35
Europe, US
HFO MDI, Propellant in MDI, HFA MDI
AstraZeneca
Mucociliary Clearance
07/24
07/24
Sun, Weijing
NCT03488667: Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Active, not recruiting
2
40
US
Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab
University of Kansas Medical Center, Merck Sharp & Dohme LLC
Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
04/24
04/25
daNIS-3, NCT04952753 / 2021-000553-40: Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

Completed
2
204
Europe, Canada, Japan, US, RoW
NIS793, Bevacizumab, Modified FOLFOX6, 5FU+Leucovorin+Oxaliplatin, FOLFIRI, 5FU+Leucovorin+Irinotecan, Tislelizumab, VDT482
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Colorectal Cancer
01/25
01/25
NCT04169347: FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Active, not recruiting
2
27
US
Oxaliplatin, Irinotecan, Leucovorin, Panitumumab
Criterium, Inc., Amgen
Colorectal Cancer Metastatic
12/24
01/25
Ascherman, Dana
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
Ortiz, Luis A
STRONG-HF, NCT03412201 / 2018-000486-37: Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP testinG, of Heart Failure Therapies

Recruiting
N/A
1800
Europe, RoW
Usual Care, High Intensity Care
Heart Initiative, Hôpitaux Universitaires Saint-Louis-Lariboisière, Momentum Research, Inc., Roche Diagnostics, Inserm UMRS 942
Heart Failure
10/21
10/21
Wisner, Katherine L
NCT03511118: Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting
N/A
1600
Canada, US
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
07/26
07/27
Burns, Timothy
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
RAMP-202, NCT04620330 / 2020-004265-39: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Checkmark Trial initiated for LGSOC and KRAS mutated NSCLC
Dec 2020 - Dec 2020: Trial initiated for LGSOC and KRAS mutated NSCLC
Completed
2
90
Europe, US
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation
08/23
12/23
NCT05567055: Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

Withdrawn
2
35
NA
Capmatinib, Tabrecta
Timothy Burns, MD, PHD, Novartis
Non-small Cell Lung Cancer
09/26
09/28
REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer

Checkmark Data from a trial for NSCLC
Jan 2022 - Jan 2022: Data from a trial for NSCLC
Active, not recruiting
1/2
284
Europe, Japan, US, RoW
CLN-081, TAS6417; zipalertinib
Cullinan Therapeutics Inc.
Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
12/24
12/24
KontRASt-01, NCT04699188 / 2020-004129-22: Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Active, not recruiting
1/2
344
Europe, Canada, Japan, US, RoW
JDQ443, TNO155, tislelizumab
Novartis Pharmaceuticals
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
04/26
04/26
UPGRADE, NCT04907968: Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer

Terminated
1
31
US
XMT-1536 (Upifitamab Rilsodotin), XMT-1536, UpRi, Carboplatin
Mersana Therapeutics, IQVIA Biotech, PSI CRO
Platinum-sensitive Ovarian Cancer (UPGRADE-A)
10/23
10/23
NCT06147037: A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours

Recruiting
1
110
Canada, US
FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
Fusion Pharmaceuticals Inc., AstraZeneca
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
12/26
12/27
NCT06561685: A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Recruiting
1
160
Japan, US
LY4050784
Eli Lilly and Company, Loxo Oncology, Inc.
Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
10/27
10/27
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Recruiting
1
250
Europe, US, RoW
MYTX-011
Mythic Therapeutics
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
12/25
12/27
DeCastro, Laura
SPARTAN, NCT03938454: A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism

Completed
2
36
US
crizanlizumab, SEG101
Novartis Pharmaceuticals
Priapism
03/23
11/23
Sciurba, Frank C
INHALE, NCT06135324: Impairments That Affect Correct Inhaler Use in COPD

Recruiting
N/A
500
US
COPD Foundation, Viatris Inc.
COPD
12/24
07/25
ZEVR, NCT04186546: Zephyr Valve Registry

Active, not recruiting
N/A
150
US
Zephyr Valve Procedure, Zephyr Endobronchial Valve, Endobronchial Valve, Bronchoscopic Lung Volume Reduction, BLVR
Pulmonx Corporation
Emphysema
12/24
12/26
RheSolve, NCT04677465: Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis

Active, not recruiting
N/A
270
Europe, US
RheOx Bronchial Rheoplasty, Sham Procedure
Gala Therapeutics, Inc.
Chronic Bronchitis
05/24
10/25
 

Download Options